Literature DB >> 20238243

Decreased prohepcidin levels in patients with HBV-related liver disease: relation with ferritin levels.

Oya Yonal1, Filiz Akyuz, Kadir Demir, Sevgi Ciftci, Fahriye Keskin, Binnur Pinarbasi, Ahmet Uyanikoglu, Halim Issever, Sadakat Ozdil, Gungor Boztas, Fatih Besisik, Sabahattin Kaymakoglu, Yilmaz Cakaloglu, Zeynel Mungan, Atilla Okten.   

Abstract

BACKGROUND: Levels of prohepcidin, a homeostatic regulator of iron absorption, are altered in chronic hepatitis C and liver cirrhosis. However, data on the potential alterations of prohepcidin in patients with HBV-related liver disease are scarce. We investigated whether serum prohepcidin is related to iron overload and perenchymal dysfuction in HBV-related liver disease.
METHODS: Three groups of subjects were studied: 66 patients with chronic hepatitis B, 32 patients with HBV-related cirrhosis, and 42 healthy controls without evidence of liver disease. Serum levels of prohepcidin were determined by enzyme-linked immunosorbent assay.
RESULTS: Serum prohepcidin levels were significantly lower in patients with HBV-related cirrhosis (175.85 ± 71.5 ng/ml) than in patients with chronic hepatitis B (209.02 ± 62.7 ng/ml P < 0.05) and controls (222.4 ± 128.4 ng/ml, P < 0.05). After adjustment for potential confounders, prohepcidin was found to be an independent predictor of ferritin levels in multiple linear regression analysis (β = -1.10, t = -3.11, P < 0.01).
CONCLUSION: These results demonstrate that prohepcidin levels are reduced in patients with HBV-related cirrhosis and are an independent correlate of serum ferritin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20238243     DOI: 10.1007/s10620-010-1183-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  17 in total

1.  Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C.

Authors:  Christopher A Aoki; Lorenzo Rossaro; Rajendra Ramsamooj; David Brandhagen; Mary F Burritt; Christopher L Bowlus
Journal:  J Clin Gastroenterol       Date:  2005-01       Impact factor: 3.062

Review 2.  Iron and liver diseases.

Authors:  S Fargion; M Mattioli; A L Fracanzani; G Fiorelli
Journal:  Can J Gastroenterol       Date:  2000-11       Impact factor: 3.522

Review 3.  Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.

Authors:  Tomas Ganz
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

Review 4.  Hepcidin--a peptide hormone at the interface of innate immunity and iron metabolism.

Authors:  T Ganz
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

5.  Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C.

Authors:  E Tsochatzis; G V Papatheodoridis; V Koliaraki; E Hadziyannis; G Kafiri; E K Manesis; A Mamalaki; A J Archimandritis
Journal:  J Viral Hepat       Date:  2010-11       Impact factor: 3.728

Review 6.  The role of hepcidin in iron metabolism.

Authors:  Elizabeta Nemeth; Tomas Ganz
Journal:  Acta Haematol       Date:  2009-11-10       Impact factor: 2.195

7.  Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis.

Authors:  Omer Fatih Olmez; Selim Gurel; Yusuf Yilmaz
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-04       Impact factor: 2.566

8.  Serum measures of iron status and HFE gene mutations in patients with hepatitis B virus infection.

Authors:  Tahereh Ghaziani; Seyed-Moayed Alavian; Mohammad R Zali; Saeid Shahraz; Mohammdreza Agah; Kevin P Jensen; Shahin Ansari; Hossein Sendi; Richard W Lambrecht; Jonathan Covault; Herbert L Bonkovsky
Journal:  Hepatol Res       Date:  2007-03       Impact factor: 4.288

9.  Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C.

Authors:  Naoki Fujita; Ryosuke Sugimoto; Masaki Takeo; Naohito Urawa; Rumi Mifuji; Hideaki Tanaka; Yoshinao Kobayashi; Motoh Iwasa; Shozo Watanabe; Yukihiko Adachi; Masahiko Kaito
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

10.  Serum prohepcidin reflects the degree of liver function impairment in liver cirrhosis.

Authors:  Jerzy Jaroszewicz; Magdalena Rogalska; Robert Flisiak
Journal:  Biomarkers       Date:  2008-08       Impact factor: 2.658

View more
  5 in total

1.  Abnormal serum iron markers in chronic hepatitis B virus infection may be because of liver injury.

Authors:  WeiLin Mao; Ying Hu; YuFeng Lou; YueMei Chen; JuanWen Zhang
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-02       Impact factor: 2.566

Review 2.  Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker.

Authors:  Driton Vela
Journal:  Mol Med       Date:  2018-03-15       Impact factor: 6.354

3.  Iron metabolism disorders in patients with hepatitis B-related liver diseases.

Authors:  Yan-Hang Gao; Jing-Yun Wang; Pei-Yan Liu; Jing Sun; Xiao-Mei Wang; Rui-Hong Wu; Xiu-Ting He; Zheng-Kun Tu; Chun-Guang Wang; Hong-Qin Xu; Jun-Qi Niu
Journal:  World J Clin Cases       Date:  2018-11-06       Impact factor: 1.337

4.  Decreased serum hepcidin concentration correlates with brain iron deposition in patients with HBV-related cirrhosis.

Authors:  Dong Lin; Jing Ding; Jian-Ying Liu; Yi-Feng He; Zhi Dai; Cai-Zhong Chen; Wei-Zhong Cheng; Jian Zhou; Xin Wang
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

5.  Correlation of serum hepcidin levels with disease progression in hepatitis B virus-related disease assessed by nanopore film based assay.

Authors:  Jing Wang; Ailian Dong; Gang Liu; Gregory J Anderson; Tony Y Hu; Jian Shi; Yulin Hu; Guangjun Nie
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.